Trials / Conditions / Refractory Waldenstrom Macroglobulinemia

Refractory Waldenstrom Macroglobulinemia

7 registered clinical trials studyying Refractory Waldenstrom Macroglobulinemia — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia NCT07420959	Mayo Clinic	Phase 1 / Phase 2
Recruiting	Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810	Mayo Clinic	Phase 1
Withdrawn	Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lym NCT04635683	Yazeed Sawalha	Phase 1
Terminated	Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinem NCT03506373	Mayo Clinic	Phase 2
Terminated	Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymph NCT03269552	University of Washington	Phase 2
Completed	Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic L NCT02332980	Mayo Clinic	Phase 2
Terminated	Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia NCT01198067	M.D. Anderson Cancer Center	Phase 1